3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
cyclopia sequence
6
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Breast Neoplasms
6
Lung Neoplasms
4
Dyspnea
4
Recurrence
3
Primary Myelofibrosis
3
Oropharyngeal Neoplasms
3
Multiple Myeloma
3
Esophageal Neoplasms
3
Carcinoma, Squamous Cell
3
Squamous Cell Carcinoma of Head and Neck
2
Polycythemia Vera
2
Pain
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thrombocythemia, Essential
1
Splenomegaly
1
Speech
1
Sezary Syndrome
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Plexosarcoma
1
Pathologic Complete Response
1
Interventions
Carboplatin
44
Paclitaxel
42
Cisplatin
20
Topotecan
17
Gemcitabine
16
Docetaxel
13
Bevacizumab
13
liposomal doxorubicin
7
olaparib
6
Cyclophosphamide
6
pembrolizumab
5
Surgical Procedures, Operative
5
Filgrastim
5
Etoposide
5
Drug Therapy
5
Amifostine
5
sargramostim
4
oregovomab
4
catumaxomab
4
anlotinib
4
Imatinib Mesylate
4
Hyperthermic Intraperitoneal Chemotherapy
4
rucaparib
3
pegfilgrastim
3
niraparib
3
ixabepilone
3
aldesleukin
3
Standard of Care
3
Peripheral Blood Stem Cell Transplantation
3
Oxaliplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Ovarian Epithelial
×
Surveys and Questionnaires
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled